ClinicalTrials.gg
RecruitingNCT06027099CARESUpdated May 6, 2026

CARES (Comprehensive Analgesic, Recovery, and Education Support) for Surgery Trial

A Phase 3 interventional study of Tizanidine and MI-Opioid Taper in Chronic Pain, Back Pain and Neck Pain, sponsored by Stanford University. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Stanford University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Chronic Pain by Stanford University — 14 open to participants now, 18 under way, 1 of them phase 3. Chronic Pain · Stanford University.

Planned enrollment
5th of 37
375 · median 80
Started
2024
with 6 others
Phase 3
2 of 47
1 open now
Primary completion
2028-01
later than 14 of 17 live
Registered
37th of 47
by date

Among the 47 studies in Chronic Pain by Stanford University, this one is the 5th largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 14 of the 17 other live ones, and was the 37th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 47 studies in Chronic Pain by Stanford University are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Chronic Pain by Stanford University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether a combined behavioral and pharmacologic intervention can help reduce opioid use, improve pain recovery, and prevent opioid misuse after surgery in adults undergoing elective surgery. The study includes adults aged 18 to 75 who have a history of long-term opioid use, defined as having access to opioids for 60 or more days within the 180 days before surgery.

The main questions it aims to answer are:

  • Does Motivational Interviewing with guided opioid tapering plus tizanidine (MI-Opioid Taper + Tizanidine) help participants return to their preoperative opioid use level or stop opioids faster than Enhanced Usual Care (EUC)?
  • Does the intervention reduce the time to pain resolution and decrease the likelihood of opioid misuse after surgery compared to EUC?

Researchers will compare MI-Opioid Taper + Tizanidine to MI-Opioid Taper with placebo and to EUC to see whether the intervention improves postoperative opioid and pain outcomes.

Participants will:

  • Complete a phone assessment and baseline survey before surgery
  • Be randomly assigned 7-13 days after surgery to one of three groups:

    • MI-Opioid Taper + tizanidine (MTT)
    • MI-Opioid Taper + placebo (MTP)
    • Enhanced Usual Care (EUC)
  • Complete brief weekly phone or video visits with a study clinician for 6 weeks starting 14 days after surgery
  • Take a study medication (tizanidine or placebo) three times daily for 5 weeks (MTT and MTP groups only)
  • Complete weekly online surveys for 6 months, followed by monthly surveys until 12 months after surgery to track pain, opioid use, and related outcomes
Read the detailed description

This is a Type 1 hybrid effectiveness-implementation, three-arm, parallel randomized controlled trial (RCT) evaluating a behavioral-pharmacologic intervention for postoperative opioid management in patients with preoperative long-term opioid use (LTOU). A total of 375 participants will be enrolled across four academic medical centers:

  • Stanford University Medical Center,
  • Harvard University- Brigham and Women's Hospital,
  • Wake Forest University- Atrium Health Wake Forest Baptist Medical Center, and
  • University of Kansas Medical Center.

Eligible participants will be randomized in equal allocation to one of three study conditions:

  • Motivational Interviewing-Guided Opioid Taper combined with tizanidine (MI-Opioid Taper + Tizanidine),
  • MI-Opioid Taper with placebo, or
  • Enhanced Usual Care (EUC). Participants will be followed for 12 months following surgery, with structured assessments of opioid use, pain outcomes, and related behavioral and clinical measures.

The primary endpoint is time to return to baseline opioid use. Secondary endpoints include time to opioid cessation, time to opioid dispensing cessation, time to pain cessation, and incidence of postoperative opioid misuse. Additional exploratory analyses will examine behavioral and clinical mediators of treatment effects, including motivation for change, change talk, and pain reduction.

Effect modification analyses will assess whether baseline participant characteristics are associated with differential treatment engagement and outcomes. Implementation outcomes will be evaluated using a mixed-methods approach guided by the RE-AIM framework, focusing on barriers and facilitators to future dissemination and scalability of the MI-Opioid Taper intervention.

This project addresses a critical gap in postoperative care for patients with long-term opioid use in need of precision postoperative pain care to minimize opioid-related harms.

03

Conditions studied

  • Chronic Pain
  • Back Pain
  • Neck Pain
  • Opioid Misuse
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 75 years of age
  • Able to speak, write, and read fluently in English
  • Scheduled for elective surgery at

    • Stanford University Medical Center,
    • Brigham and Women's Hospital (Harvard University),
    • Atrium Health Wake Forest Baptist Medical Center (Wake Forest University), or
    • University of Kansas Medical Center
  • Preoperative long-term opioid use (Defined as ≥ 60-day supply of opioids in the 180-day period prior to surgery), identified via self-report, state Prescription Drug Monitoring Program (PDMP), or Electronic Medical Records (EHR). Days may be nonconsecutive, and actual use of opioid supply is not required.
  • Willing and able to complete online assessments and study calls independently
  • On the preoperative Baseline assessments, least one of the following:

    • Current Opioid Misuse Measure (COMM-17): score ≥ 9
    • Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS-1): Reported use more frequent than "Never" on any item except Tobacco; for Tobacco, "Yes" to at least one item on the TAPS-2 for Tobacco
    • Alcohol Use Disorders Identification Test (AUDIT-C): score ≥4 (men), ≥3 (women)
    • Modified Brief Pain Inventory (mBPI): "Yes" to at least one of the following:

      • Over the past 24 hours have you needed to take your pain medication to help you sleep?
      • Have you taken any pain medications for any reason other than your pain, such as to reduce anxiety or improve mood?
      • Have you taken more pain medication than was prescribed to you in the past 24 hours?
  • At the Post-Operative Call (7-13 days post-op): Postoperative daily opioid dose ≥ preoperative daily opioid dose (identified during the Pre-Surgery Call 5-1 day before surgery), measured in Morphine Milligram Equivalents (MME).

Exclusion criteria

EXCLUSION CRITERIA

  • Infection, tumor, or fracture at the operative site
  • Allergy or intolerance to tizanidine
  • Current use of tizanidine
  • Renal impairment ( [CrCl] \< 25 ml/min)
  • Hepatic impairment, including cirrhosis or elevated liver enzymes
  • Concurrent use of other α2-adrenergic agonists, skeletal muscle relaxants
  • Concurrent use of: fluvoxamine, ciprofloxacin,zileuton, fluoroquinolones, antiarrhythmics (amiodarone, mexiletine, propafenone, verapamil), cimetidine, famotidine, oral pills, acyclovir, ticlopidine, and fexinidazole
  • Pre-existing hypotension, sedation, dizziness, severe respiratory insufficiency.
  • Opioid Use Disorder
  • Suicidality as assessed by the Patient Health Questionnaire-9 (PHQ-9) Question 9 score ≥ 1
  • Pregnancy, breastfeeding, or planning to conceive
  • Planned cancer treatment in the \< 3 months following surgery
  • Conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)
  • Participating in another clinical trial with an active treatment arm
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    MI-Opioid Taper and tizanidine

    Drug: Tizanidine · Behavioral: MI-Opioid Taper

  • Experimental
    MI-Opioid Taper and placebo

    Behavioral: MI-Opioid Taper · Drug: Placebo

  • Active comparator
    Enhanced Usual Care

    Behavioral: Enhanced Usual Care

Interventions

  • Tizanidine 2mg three times a day for 5 weeks after surgery

  • BehavioralMI-Opioid Taper

    Motivational Interviewing (MI) and guided Opioid Tapering support adapting MI principles for enhancing motivation to change in pain treatment and tailoring key MI tools to postoperative opioid use delivered through weekly phone calls from weeks 2 to 7, and at week 11. The guided opioid tapering protocol will be a 25% total daily opioid dose reduction every 7 days with opioid discontinuation 7 days after reaching 1 opioid pill per day.

  • DrugPlacebo

    1 tablet three times a day for 5 weeks after surgery

  • BehavioralEnhanced Usual Care

    Participants will receive weekly phone calls from weeks 2 to 7, and at week 11. 1 topic per call will be reviewed in this sequence:1) standardized instructions on taking opioid medications after surgery, 2) safe opioid use, 3) avoiding medication errors, 4) local mental health resources and 988 Suicide \& Crisis lifeline, 5) disposal of unused medications, 6) prescription drug abuse, and 7) complementary health approaches for chronic pain. Education materials will be reviewed in a didactic style without a tailored discussion.

06

What researchers measure

Primary outcomes

  1. Time to Baseline Opioid Use

    Defined as the first of two consecutive reports of return to preoperative daily MME or lower on the modified Brief Pain Inventory (mBPI) or the Recent Opioid Medication Use survey. Preoperative daily MME use is defined as average daily MME assessed during the Preoperative Call in the 1-5 day window prior to surgery.

    Time frame: From Postoperative Day 7 through Postoperative Day 365

Secondary outcomes

  1. Time to Complete Opioid Cessation

    First of two consecutive reports of opioid cessation on the modified Brief Pain Inventory (mBPI) or the Recent Opioid Medication Use survey.

    Time frame: From Postoperative Day 7 through Postoperative Day 365

  2. Time to Opioid Dispensing Cessation

    Via state Prescription Drug Monitoring Program (PDMP): First day in the first gap in opioid prescribing ≥ 30 days after surgery

    Time frame: From Postoperative Day 7 through Postoperative Day 365

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2028, 37 months after the start.

Of 49 phase 3 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2023
First posted
Sep 7, 2023
StartActual
Dec 5, 2024
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06027099
Responsible party
Jennifer Hah (Associate Professor, Stanford University) — Principal investigator
First posted
Sep 7, 2023
Start date
Dec 5, 2024
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
May 6, 2026

Study contacts

Shana C Levine, BA, CARES RESEARCH COORDINATOR
Contact
Shana8@stanford.edu
650-649-9618
SPARKLE (Strategies for Pain Alleviation though Research and Knowledge for Long-term Efficacy) Lab
Contact
CARESStudy@Stanford.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tizanidine

Start the discussion